A Phase 3 interventional study of DCV and SOF in Hepatitis C, sponsored by Bristol-Myers Squibb. Completed at 19 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-05-08.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies testing daclatasvir in Hepatitis C — 1 open to participants now, 2 under way, 1 of them phase 3. daclatasvir · Hepatitis C.
Among the 59 studies testing daclatasvir in Hepatitis C, this one is the 28th largest by enrollment, is one of 5 that started in 2016, is one of 24 in phase 3, and was the 50th registered.
1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.
Browse Hepatitis C studies →1 of the 59 studies testing daclatasvir in Hepatitis C is open now, in 1 country. Recruiting first, the newest first:
Tanta University · Sites in Egypt
Ages 18+
By country, each count listing its studies:
daclatasvir: first FDA approval 2015 (DAKLINZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 18 · Phase 3 25 · Phase 4 5
First in 2009; this study’s year is marked. 5 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 106 is above the median of 73 across 1,224 interventional studies indexed under Hepatitis C.
Median enrollment 100 across the 59 interventional studies. Of the 53 that completed or were terminated, 25 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 59 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
78 studies in Hepatitis C by Bristol-Myers Squibb: none open now, none under way, none of them phase 3. Of 70 finished, 25 (36%) have results posted.
Among the 78 studies in Hepatitis C by Bristol-Myers Squibb, this one is the 31st largest by enrollment of the 67 interventional ones that give a count, is one of 2 that started in 2016, is one of 26 in phase 3, and was the 71st registered.
Bristol-Myers Squibb’s Hepatitis C studies by the year they started, since 2007.
None of the studies under way reaches primary completion within a year.
Among the 59 studies testing daclatasvir in Hepatitis C, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 78 in Hepatitis C:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether 24 weeks of Daclatasvir and Sofosbuvir with Ribavirin is safe and effective in the treatment of genotype 3 hepatitis C infected patients with liver cirrhosis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding Bristol-Myers Squibb (BMS) Clinical Trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria could apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral dosing of DCV 60 mg tablet once daily + SOF 400 mg tablet once daily + RBV 1000-1200 mg tablet per day (weight based) for 24 weeks.
Drug: DCV · Drug: SOF · Drug: RBV
Percentage of Participants With Sustained Virologic Response (SVR12)
SVR12 was defined as hepatitis C virus (HCV) RNA less than the lower limit of quantitation, target detected or target not detected at follow-up Week 12. HCV RNA measurements are excluded after the start of non-study anti-HCV medication on treatment or during follow-up. Modified (mITT) approach is based on treated subjects. The numerator is based on subjects meeting the response criteria and the Next Value Carried Backwards approach.
Time frame: Week 12
Percentage of Participants Who Achieve SVR12 in the Presence and Absence of Baseline NS5A (Non-structural Protein 5A) Resistance-associated Polymorphisms
SVR12 was defined as hepatitis C virus (HCV) RNA less than the lower limit of quantitation, target detected or target not detected at follow-up Week 12. HCV RNA measurements are excluded after the start of non-study anti-HCV medication on treatment or during follow-up. Modified (mITT) approach is based on treated subjects. The numerator is based on subjects meeting the response criteria and the Next Value Carried Backwards approach.
Time frame: Week 12 (Follow-up period)
Percentage of Subjects Who Achieve HCV RNA < LLOQ, TD or TND Through Follow up Week 24
HCV RNA measurements are excluded after the start of non-study anti-HCV medication on treatment or during follow-up. Modified (mITT) approach is based on treated subjects. The numerator is based on subjects meeting the response criteria. SVR12 is based on Next Value Carried Backwards approach.
Time frame: At Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, End of Treatment (24 weeks), Follow Up Week 4 (28 weeks), Follow Up Week 12 (36 weeks), Follow Up Week 24 (48 weeks)
Percentage of Subjects Who Achieve HCV RNA < LLOQ, TND Through Follow up Week 24
HCV RNA measurements are excluded after the start of non-study anti-HCV medication on treatment or during follow-up. Modified (mITT) approach is based on treated subjects. The numerator is based on subjects meeting the response criteria.
Time frame: At Week 1, Week 2, Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, End of Treatment, Follow Up Week 4, Follow Up Week 12, Follow Up Week 24
| Milestone | Treatment Naive | Treatment Experienced |
|---|---|---|
| Started | 54 | 24 |
| Completed | 49 | 21 |
| Not completed | 5 | 3 |
| Withdrew: Lost to follow-up | 3 | 0 |
| Withdrew: Participant request to discontinue | 1 | 1 |
| Withdrew: Participant moved to another province | 1 | 0 |
| Withdrew: Participant was incarcerated | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 |
| Milestone | Treatment Naive | Treatment Experienced |
|---|---|---|
| Started | 50 | 23 |
| Completed | 50 | 21 |
| Not completed | 0 | 2 |
| Withdrew: Unable to return for week 24 follow-up | 0 | 1 |
| Withdrew: Unable to return for follow-up | 0 | 1 |
SVR12 was defined as hepatitis C virus (HCV) RNA less than the lower limit of quantitation, target detected or target not detected at follow-up Week 12. HCV RNA measurements are excluded after the start of non-study anti-HCV medication on treatment or during follow-up. Modified (mITT) approach is based on treated subjects. The numerator is based on subjects meeting the response criteria and the Next Value Carried Backwards approach.
| Percentage of participants | HCV Treatment Naive | HCV Treatment Experienced |
|---|---|---|
| Percentage of Participants With Sustained Virologic Response (SVR12) | 92.6 (82.1 to 97.9) | 75.0 (53.3 to 90.2) |
SVR12 was defined as hepatitis C virus (HCV) RNA less than the lower limit of quantitation, target detected or target not detected at follow-up Week 12. HCV RNA measurements are excluded after the start of non-study anti-HCV medication on treatment or during follow-up. Modified (mITT) approach is based on treated subjects. The numerator is based on subjects meeting the response criteria and the Next Value Carried Backwards approach.
| Percentage of participants | HCV Treatment Naive | HCV Treatment Experienced |
|---|---|---|
| NS5A-Y93 Polymorphism: YES | 85.7 (42.1 to 99.6) | 0.0 (0.0 to 97.5) |
| NS5A-Y93 Polymorphism: NO | 93.6 (82.5 to 98.7) | 78.3 (56.3 to 92.5) |
HCV RNA measurements are excluded after the start of non-study anti-HCV medication on treatment or during follow-up. Modified (mITT) approach is based on treated subjects. The numerator is based on subjects meeting the response criteria. SVR12 is based on Next Value Carried Backwards approach.
| Percentage | HCV Treatment Naive | HCV Treatment Experienced |
|---|---|---|
| Week 1 | 14.8 (6.6 to 27.1) | 12.5 (2.7 to 32.4) |
| Week 2 | 50.0 (36.1 to 63.9) | 54.2 (32.8 to 74.4) |
| Week 4 | 92.6 (82.1 to 97.9) | 75.0 (53.3 to 90.2) |
| Week 8 | 98.1 (90.1 to 100.0) | 91.7 (73.0 to 99.0) |
| Week 12 | 92.6 (82.1 to 97.9) | 87.5 (67.6 to 97.3) |
| Week 16 | 90.7 (79.7 to 96.9) | 83.3 (62.6 to 95.3) |
| Week 20 | 94.4 (84.6 to 98.8) | 83.3 (62.6 to 95.3) |
| Week 24 | 88.9 (77.4 to 95.8) | 87.5 (67.6 to 97.3) |
| End of Treatment | 100.0 (93.4 to 100.0) | 91.7 (73.0 to 99.0) |
| Follow Up Week 4 | 88.9 (77.4 to 95.8) | 79.2 (57.8 to 92.9) |
| Follow Up Week 12 (Imputed) | 92.6 (82.1 to 97.9) | 75.0 (53.3 to 90.2) |
| Follow Up Week 24 | 92.6 (82.1 to 97.9) | 66.7 (44.7 to 84.4) |
HCV RNA measurements are excluded after the start of non-study anti-HCV medication on treatment or during follow-up. Modified (mITT) approach is based on treated subjects. The numerator is based on subjects meeting the response criteria.
| Percentage | HCV Treatment Naive | HCV Treatment Experienced |
|---|---|---|
| Week 1 | 1.9 (0.0 to 9.9) | 0.0 (0.0 to 14.2) |
| Week 2 | 11.1 (4.2 to 22.6) | 12.5 (2.7 to 32.4) |
| Week 4 | 64.8 (50.6 to 77.3) | 62.5 (40.6 to 81.2) |
| Week 8 | 94.4 (84.6 to 98.8) | 83.3 (62.6 to 95.3) |
| Week 12 | 90.7 (79.7 to 96.9) | 83.3 (62.6 to 95.3) |
| Week 16 | 90.7 (79.7 to 96.9) | 79.2 (57.8 to 92.9) |
| Week 20 | 94.4 (84.6 to 98.8) | 83.3 (62.6 to 95.3) |
| Week 24 | 88.9 (77.4 to 95.8) | 83.3 (62.6 to 95.3) |
| End of Treatment | 100.0 (93.4 to 100.0) | 87.5 (67.6 to 97.3) |
| Follow Up Week 4 | 88.9 (77.4 to 95.8) | 79.2 (57.8 to 92.9) |
| Follow Up Week 12 | 90.7 (79.7 to 96.9) | 75.0 (53.3 to 90.2) |
| Follow Up Week 24 | 90.7 (79.7 to 96.9) | 66.7 (44.7 to 84.4) |
Collected over From first dose until last dose plus 7 days (assessed up to May 2017, approximately 14 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Overall: Daclatasvir(DCV) + Sofosbuvir(SOF) + Ribavirin(RBV) | 0/78 (0%) | 8/78 (10.3%) | 63/78 (80.8%) |
| HCV Treatment Naive | 0/54 (0%) | 4/54 (7.4%) | 44/54 (81.5%) |
| HCV Treatment Experienced | 0/24 (0%) | 4/24 (16.7%) | 19/24 (79.2%) |
| Event | Overall: Daclatasvir(DCV) + Sofosbuvir(SOF) + Ribavirin(RBV) | HCV Treatment Naive | HCV Treatment Experienced |
|---|---|---|---|
| CholecystitisHepatobiliary disorders | 1/78 | 0/54 | 1/24 |
| Streptococcal bacteraemiaInfections and infestations | 1/78 | 0/54 | 1/24 |
| Accidental overdoseInjury, poisoning and procedural complications | 2/78 | 1/54 | 1/24 |
| DepressionPsychiatric disorders | 1/78 | 0/54 | 1/24 |
| AscitesGastrointestinal disorders | 1/78 | 1/54 | 0/24 |
| Chest discomfortGeneral disorders | 1/78 | 1/54 | 0/24 |
| BronchiolitisInfections and infestations | 1/78 | 1/54 | 0/24 |
| OverdoseInjury, poisoning and procedural complications | 1/78 | 1/54 | 0/24 |
| Event | Overall: Daclatasvir(DCV) + Sofosbuvir(SOF) + Ribavirin(RBV) | HCV Treatment Naive | HCV Treatment Experienced |
|---|---|---|---|
| FatigueGeneral disorders | 34/78 | 21/54 | 13/24 |
| HeadacheNervous system disorders | 22/78 | 14/54 | 8/24 |
| NauseaGastrointestinal disorders | 19/78 | 13/54 | 6/24 |
| InsomniaPsychiatric disorders | 14/78 | 11/54 | 3/24 |
| AnaemiaBlood and lymphatic system disorders | 10/78 | 6/54 | 4/24 |
| DizzinessNervous system disorders | 6/78 | 3/54 | 3/24 |
| IrritabilityPsychiatric disorders | 7/78 | 6/54 | 1/24 |
| ToothacheGastrointestinal disorders | 5/78 | 3/54 | 2/24 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 5/78 | 3/54 | 2/24 |
| AnxietyPsychiatric disorders | 5/78 | 3/54 | 2/24 |
| Age, Continuous(Years) | Treatment Naive | Treatment Experienced | Total |
|---|---|---|---|
| Mean | 54 ± 7.97 | 55.3 ± 4.90 | 54.4 ± 7.16 |
| Sex: Female, Male(Participants) | Treatment Naive | Treatment Experienced | Total |
|---|---|---|---|
| Female | 14 | 7 | 21 |
| Male | 40 | 17 | 57 |
| Ethnicity (NIH/OMB)(Participants) | Treatment Naive | Treatment Experienced | Total |
|---|---|---|---|
| Hispanic or Latino | 7 | 6 | 13 |
| Not Hispanic or Latino | 20 | 8 | 28 |
| Unknown or Not Reported | 27 | 10 | 37 |
| Race (NIH/OMB)(Participants) | Treatment Naive | Treatment Experienced | Total |
|---|---|---|---|
| American Indian or Alaska Native | 2 | 0 | 2 |
| Asian | 4 | 3 | 7 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 48 | 21 | 69 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2016 to primary completion in Mar 2017, 11 months.
Results were first posted in Mar 2018, 1 year after primary completion.
Of 68 industry-sponsored phase 3 interventional studies under Hepatitis C, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 18. This study's 11 months is below that.
Counting every sponsor, half of 90 studies reached it within 14 months; a quarter within 10 and three quarters within 22.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Daclatasvir · Sofosbuvir · Ribavirin